Results 11 to 20 of about 18,215 (242)

Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer [PDF]

Journal of Mid-Life Health, 2022
Background: The use of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for breast cancer (BC) therapy is the subject of debate, and there is an urgent need to understand much the expression and prognostic role of the PARP1 protein.
Akanksha, Shashi Prakash Mishra, Amrita Ghosh Kar, J S Karthik, Aviral Srivastava, Rahul Khanna, Ram Niwas Meena   +6 more
doaj   +5 more sources

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. [PDF]

Cureus, 2022
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival of less than 10%. Traditional chemotherapy has been the mainstay treatment for years, with limited improvement in survival.
Sunkara T, Bandaru SS, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A.   +5 more
europepmc   +5 more sources

A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. [PDF]

CA Cancer J Clin
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair.
Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, Golan T, Litton JK, Swami U, Moore KN, Agarwal N.   +10 more
europepmc   +4 more sources

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. [PDF]

Cancer, 2020
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance.
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC.   +17 more
europepmc   +4 more sources

Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis. [PDF]

PLoS ONE, 2017
BACKGROUND:Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic
Weiqiang Qiao, Linlin Pan, Changgui Kou, Ke Li, Ming Yang   +4 more
doaj   +3 more sources

Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma. [PDF]

Cureus, 2022
Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a germline BRCA1 mutation and a stage IV OCS who was proposed olaparib maintenance therapy after ...
Magalhães D, Bartosch C, Abreu MH.
europepmc   +2 more sources

Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted ¹⁸F-Fluorthanatrace PET Images of Ovarian Cancer. [PDF]

J Nucl Med, 2022
Visual Abstract The poly-(adenosine diphosphate-ribose) polymerase (PARP) family of proteins participates in numerous functions, most notably the DNA damage response.
Young AJ, Pantel AR, Viswanath V, Dominguez TL, Makvandi M, Lee H, Li S, Schubert EK, Pryma DA, Farwell MD, Mach RH, Simpkins F, Lin LL, Mankoff DA, Doot RK.   +14 more
europepmc   +2 more sources

Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report. [PDF]

J Int Med Res, 2021
A 57-year-old woman was diagnosed with IDH-wildtype (IDHwt) astrocytoma (World Health Organization grade II) with the molecular characteristics of glioblastoma.
Wang Z, Ren Y, Du F, Sun Y, Jiang W.
europepmc   +2 more sources

Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review. [PDF]

Cureus
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have appeared as a revolutionary approach to treating advanced ovarian cancer, particularly in patients with breast cancer (BRCA) mutations and homologous recombination deficiency (HRD ...
Dewani D, Jaiswal A, Karwade P.
europepmc   +2 more sources

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors. [PDF]

Oncotarget, 2017
Poly(ADP-ribose) polymerases are a family of DNA-dependent nuclear enzymes catalyzing the transfer of ADP-ribose moieties from cellular nicotinamide-adenine-dinucleotide to a variety of target proteins.
Cseh AM, Fábián Z, Sümegi B, Scorrano L.   +3 more
europepmc   +2 more sources